Clinical Trial Update: Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia [Phase 2]

View source ↗

Summary

Open-label, long-term extension study of infigratinib in children with hypochondroplasia is currently enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypochondroplasia

Drugs mentioned

• Infigratinib (infigratinib)

Snippet

Sponsor: QED Therapeutics, a BridgeBio company | Conditions: Hypochondroplasia | Phase 2 | Status: ENROLLING_BY_INVITATION